Zenocutuzumab, a bsAb targeting HER3 and HER2, has shown promising results, especially in disrupting HER2/HER3/NRG1 complex formation, and was recently approved by the FDA for NRG1-fusion-positive NSCLC [182]. Here, NRG1 is linked to non-small cell lung carcinoma.